Edition:
United Kingdom

Alpine Immune Sciences Inc (ALPN.OQ)

ALPN.OQ on NASDAQ Stock Exchange Global Market

10.98USD
6:17pm GMT
Change (% chg)

$-0.13 (-1.17%)
Prev Close
$11.11
Open
$11.10
Day's High
$11.10
Day's Low
$10.90
Volume
1,568
Avg. Vol
10,321
52-wk High
$14.52
52-wk Low
$7.30

Summary

Name Age Since Current Position

Mitchell Gold

50 2017 Executive Chairman of the Board, Chief Executive Officer, Assistant Secretary

Jay Venkatesan

45 2017 President, Director

Paul Rickey

38 2017 Chief Financial Officer, Senior Vice President, Secretary

Stanford Peng

46 2017 Executive Vice President - Research and Development, Chief Medical Officer

Sherif Gabriel

54 2012 Vice President – Research and Discovery

Steven Shoemaker

64 2014 Vice President – Clinical Research and Development, Medical Director

Peter Thompson

2017 Director

James Topper

54 2017 Director

Robert Conway

62 Independent Director

Paul Sekhri

59 2016 Independent Director

Biographies

Name Description

Mitchell Gold

Dr. Mitchell H. Gold, M.D. is Executive Chairman of the Board, Chief Executive Officer, Assistant Secretary of the company. He has served as Alpine’s acting Chief Executive Officer since June 2016 and has served as Executive Chairman and as a member of Alpine’s board of directors since January 2015. Prior to co-founding Alpine, Dr. Gold was Chairman and Founder of Alpine Biosciences, a privately-held biotech company, from 2012 to 2014. From 2001 to 2012, Dr. Gold served in a variety of roles with Dendreon Corporation (which has since been acquired by Valeant Pharmaceuticals International, Inc. through an asset purchase agreement), including President, Chief Executive Officer, and Chairman of the board of directors. Earlier in his career, Dr. Gold served as Vice President of Business Development at Data Critical from 2000 to 2001. From 1995 to 2000, Dr. Gold was President and Chief Executive Officer of Elixis Corporation. Dr. Gold holds an M.D. from Rush Medical College of Rush University Medical Center and a B.S. in Biology from the University of Wisconsin. Dr. Gold is currently a Managing Partner at Alpine BioVentures, GP LLC, a Delaware limited liability company, which is a general partner of Alpine Immunosciences, L.P., a Delaware limited partnership. In addition, Dr. Gold is also a limited partner of Alpine Immunosciences, L.P. As a result of the Merger, Alpine Immunosciences, L.P., is currently a holder of more than 5% of the Company’s outstanding common stock.

Jay Venkatesan

Dr. Jay Venkatesan, M.D. serves as President, Director of the company. He served as Alpine’s Chief Executive Officer from November 2015 to June 2016 before transitioning to Alpine’s President in June 2016. Dr. Venkatesan has served as a member of Alpine’s board of directors since November 2015. Prior to joining Alpine, Dr. Venkatesan was the Executive Vice President and General Manager of Oncothyreon, Inc. (now Cascadian Therapeutics) from August 2014 to May 2015 following Oncothyreon’s acquisition of Alpine Biosciences, where he served as co-founder and Chief Executive Officer. Previously, Dr. Venkatesan was the Founder, Portfolio Manager, and Managing Director of Ayer Capital Management, a global healthcare equity fund from 2008 to 2013. Prior to that, he was a Director at Brookside Capital Partners from 2002 to 2007. Earlier in his career, Dr. Venkatesan was involved in healthcare investing at Partricof & Co. Ventures from 1995 to 1996 and consulting at McKinsey & Company from 1993 to 1995. In addition, Dr. Venkatesan currently serves on the board of directors of Iovance Biotherapeutics (NASDAQ: IOVA) (formerly Lion Biotechnologies), Transplant Genomics, CellBioTherapy, and Exicure Therapeutics. Dr. Venkatesan received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania, and a B.A. in Chemistry from Williams College. Dr. Venkatesan is currently a Managing Partner at Alpine BioVentures, GP, LLC, a Delaware limited liability company, which is a general partner of Alpine Immunosciences, L.P., a Delaware limited partnership. In addition, Dr. Venkatesan is also a limited partner of Alpine Immunosciences, L.P. As a result of the Merger, Alpine Immunosciences, L.P., is currently a holder of more than 5% of the Company’s outstanding common stock.

Paul Rickey

Mr. Paul Rickey, CPA. serves as Chief Financial Officer, Senior Vice President, Secretary of the company. He has served as Alpine’s Senior Vice President and Chief Financial Officer since April 2017. Mr. Rickey is an experienced executive who has spent nearly 16 years guiding financial strategy in the life sciences and technology industries. Prior to his joining Alpine in 2017, Mr. Rickey served as Chief Financial Officer of Sound Pharmaceuticals, overseeing finance, accounting and human resources. Before joining Sound Pharmaceuticals in 2016, Mr. Rickey was Vice President of Finance and Administration of Immune Design Corp., (NASDAQ:IMDZ) a publicly traded biotechnology company, where he helped complete the company’s private offerings, initial public offering, and follow-on financing, and also oversaw the corporate development, accounting and human resource functions. Before joining Immune Design in 2009, Mr. Rickey was Corporate Controller of Northstar Neuroscience, a publicly-traded medical device company, where he managed the company’s finance and accounting groups following Northstar’s initial public offering. Prior to his role at Northstar Neuroscience, Mr. Rickey was the accounting manager for Mobliss, Inc., a mobile technology company that was sold to Index Corp., of Japan. Mr. Rickey started his finance career at Ernst & Young LLP. Mr. Rickey graduated from the University of Washington with a B.A. and Masters in Professional Accounting and is a Certified Public Accountant.

Stanford Peng

Dr. Stanford Peng, M.D. Ph.D. serves as Executive Vice President - Research and Development, Chief Medical Officer of the company. He has served as Alpine’s Chief Medical Officer since September 2016. In February 2017, his title was changed to Executive Vice President of Research and Development and Chief Medical Officer. Prior to joining Alpine, Dr. Peng was Chief Medical Officer and head of clinical development at Stemcentrx, providing strategic oversight of the company’s clinical and translational programs from 2015 to 2016. Previously, Dr. Peng was Executive Medical Director at Seattle Genetics where he developed multiple programs for antibody-drug conjugates from 2014 to 2015. Earlier in his career, he directed translational research and auto-immune related clinical trials as head of the Rheumatology Clinical Research Unit at the Benaroya Research Institute from 2009 to 2014 and served as Senior Director, Clinical Research and Exploratory Development at Roche from 2005 to 2008. Between 2009 and 2014, Dr. Peng also served as Member Physician at Virginia Mason Medical Center. Dr. Peng served as an Assistant Professor at the Washington University School of Medicine from 2002 to 2005. From 2008 to 2009, Dr. Peng served as Senior Director at ARYx Therapeutics, Inc. (NASDAQ: ARYX). Dr. Peng received an M.D. and Ph.D. in biology from the Yale University School of Medicine and a B.A. in music and B.S. in biological sciences from Stanford University.

Sherif Gabriel

Dr. Sherif Gabriel, Ph.D. is the Vice President – Research and Discovery of the Company, since 2012. Prior to joining Nivalis, Dr. Gabriel served as an Associate Professor of Pediatrics and the Cystic Fibrosis Center at the University of North Carolina from January 2001 to August 2012. During his tenure at the University of North Carolina, Dr. Gabriel directed the CFTR Molecular Therapy and Correction Core, and he has spent more than 20 years focused on understanding the function of CFTR, and developing treatments for CF. Dr. Gabriel earned both his B.S. and Ph.D. from the University of Saskatchewan, Saskatoon.

Steven Shoemaker

Dr. Steven Shoemaker, M.D. is the Vice President – Clinical Research and Development, Medical Director of the Company, He has served as our Vice President of Clinical Research and Development and as our Medical Director since July 2014. From September 2012 to June 2014, he served as our Director of Clinical Development and Medical Director, and from June 2007 to March 2009 he served as our Vice President of Medical Affairs. He served as the Principal of Nicosof, LLC from April 2009 to August 2012. Previously, from April 1994 to October 2000 he served as Medical Director and Vice President of Medical Affairs at Anesta Corp. and then Cephalon, Inc. that acquired Anesta in July 2000. Dr. Shoemaker has a B.S. in Chemistry from Stanford University and received his M.D. from the UCLA School of Medicine. Dr. Shoemaker's subspecialty clinical training was in Pulmonary and Critical Care Medicine at the University of Colorado Health Sciences Center.

Peter Thompson

Dr. Peter Thompson, M.D. serves as Director of the company. he has served as a member of Alpine’s board of directors since June 2016. Dr. Thompson currently serves as a Private Equity Partner for OrbiMed Advisors LLC, an investment firm focused on the healthcare sector, where he has also served as Venture Partner since joining in September 2010. OrbiMed Advisors LLC is the managing member of OrbiMed Capital GP VI LLC. OrbiMed Capital GP VI LLC is the general partner of OrbiMed Private Investments VI, LP, which is a holder of more than 5% of Alpine’s outstanding capital stock. Dr. Thompson is a co-founder of and has served as a member of the board of directors of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) since December 2014. Dr. Thompson has also served as a director of Adaptimmune Therapeutics plc (NASDAQ: ADAP), a biopharmaceutical company, since 2014 and also currently serves on the boards of directors of several private companies. Dr. Thompson is a board-certified internist and oncologist and has served as Affiliate Professor of Neurosurgery at the University of Washington since 2010. Dr. Thompson co-founded and served as the Chief Executive Officer of Trubion Pharmaceuticals, Inc., a biopharmaceutical company, from 2002 to 2009. Dr. Thompson previously held executive positions at Chiron Corporation and Becton Dickinson, and served on the faculty of the National Cancer Institute following his medical staff fellowship there. Dr. Thompson holds a Sc. B. in Molecular Biology and Mathematics from Brown University and an M.D. from Brown University Medical School.

James Topper

DR. James N. Topper, M.D. Ph.D. serves as Director of the company. He has served as a member of Alpine’s board of directors since June 2016. Dr. Topper is a managing member of FHM Life Sciences VIII, LLC, a Delaware limited liability company. FHM Life Sciences VIII, LLC is the general partner of FHM Life Sciences VIII, LP, a Delaware limited partnership. FHM Life Sciences VIII, LP is the general partner of Frazier Life Sciences VIII, L.P., a Delaware limited partnership, which is a holder of more than 5% of Alpine’s outstanding capital stock. Dr. Topper has been a partner with Frazier Healthcare Partners since August 2003, serving as General Partner since 2005. Before joining Frazier Healthcare Partners, Dr. Topper served as head of the Cardiovascular Research and Development Division of Millennium Pharmaceuticals, Inc. and ran Millennium San Francisco (formerly COR Therapeutics, Inc.) from 2002 to 2003. Before the merger of COR and Millennium in 2002, Dr. Topper served as the Vice President of Biology at COR from 1999 to 2002. Dr. Topper currently serves as a member of the board of directors of AnaptysBio, Inc. (NASDAQ: ANAB) and has served on numerous other boards of directors, including Sierra Oncology, Inc. (formerly ProNai) (NASDAQ: SRRA), Amicus Therapeutics, Inc. (NASDAQ: FOLD), Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), and La Jolla Pharmaceutical Company (NASDAQ: LJPC). Dr. Topper received his M.D. and Ph.D. in biophysics from Stanford University and his B.S. in biology from the University of Michigan.

Robert Conway

Mr. Robert E. Conway is an Independent Director of the Company. He joined our Board in April 2015. From 1999 to 2012, Mr. Conway served as the Chief Executive Officer and member of the board of directors of Array BioPharma, a publicly traded biopharmaceutical company. Prior to joining Array, Mr. Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, from 1996 to 1999. From 1979 until 1996, Mr. Conway held various executive positions for Corning Inc., including Corporate Vice President and General Manager of Corning Hazleton, a contract research organization. Since 2013, Mr. Conway has served on the Board of Directors of ARCA BioPharma, a publicly traded biopharmaceutical company, and was elected Chairman in June 2014. From 2004 to 2013, he served on the Boards of Directors of PRA International, which was a public company for a portion of his tenure there, and eResearch Technology, a private company. Mr. Conway serves as the Chairman of Wall Family Enterprise, a leading library and educational supplies company. In addition, Mr. Conway is a member of the Strategic Advisory Committee of Genstar Capital. Mr. Conway received a B.S. in accounting from Marquette University in 1976.

Paul Sekhri

Mr. Paul J. Sekhri is an Independent Director of the Company. He joined our Board in February 2016. Mr. Sekhri is the President and CEO of Lycera Corp., a position he has held since February 2015. Prior to this position, he served as Senior Vice President, Integrated Care for Sanofi from April 2014 through January 2015, and as Group